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Abstract
Background: HAART has significantly reduced AIDS-related morbidity in children. However, limited evidence is
available from developing countries regarding patterns of opportunistic illnesses. We describe these events and
their associated factors in children with AIDS in Brazil.
Methods: This study is based on two representative retrospective multi-center cohorts including a total 1,859
children with AIDS, infected via mother-to-child transmission (MTCT), between 1983-2002. Opportunistic illnesses
were described and analyzed over time. The association of demographic, clinical and operational data with the
occurrence of opportunistic diseases was assessed.
Results: In total, 1,218 (65.5%) had at least one event of an opportunistic disease. Variables significantly associated
with occurrence of these events included: region of residence (OR 2.68-11.33, as compared to the Northern region),
age < 1 year at diagnosis (OR 2.56, 95% CI 1.81-3.61, p < 0.001), and non-performance of MTCT prevention measures
(OR 1.58, 95% CI 1.21-2.07, p < 0.001). Protective factors included year of HIV diagnosis in the HAART era (OR 0.34,
95% CI 0.15-0.76, p = 0.009) and ART use (OR 0.58, 95% CI 0.44-0.77, p < 0.001). In both periods bacterial infections
represented the most common opportunistic events (58.6 vs. 34.7%; p < 0.001), followed by Pneumocystis jirovecii
pneumonia (21.9 vs. 13.2%; p < 0.001), and bacterial meningitis/sepsis (16.8 vs. 7.4%; p < 0.001).
Conclusions: Despite the significant reduction in recent years, opportunistic illnesses are still common in Brazilian
children with AIDS in the HAART era, especially bacterial diseases. The data reinforce the need for scaling up
prevention of MTCT, early diagnosis of infection, and improvement of comprehensive pediatric care.
Background
Over the past 15 years, both morbidity and mortality
associated with human immunodeficiency virus (HIV)
have been systematically reduced in children. Greater
knowledge on the clinical course, early diagnosis of HIV
infection, adoption of prophylaxis, improved manage-
ment of opportunistic diseases, and introduction of anti-
retroviral therapy (ART) contributed to this trend [1-4].
New patterns of morbidity associated with chronic dis-
eases have been described recently in HIV-infected indi-
viduals [5-7].
The adoption of highly active antiretroviral therapy
( H A A R T )a l s oh a sh a da ni m p o r t a n tr o l ei nm o d i f y i n g
the natural history of HIV infection in children, charac-
terized by a reduction of the progression to AIDS. The
limited evidence available in children exposed to HIV via
mother to child transmission (MTCT) shows reduced
rates of clinical events in category “C” of CDC revised
classification system for HIV infection. Early diagnosis of
HIV infection and HAART has led to a reduction in the
frequency of opportunistic diseases in children with sub-
sequent reduced number of hospitalizations [4,8-10].
However, severe bacterial infections, mostly pneumonia,
were still observed, even in children without severe
immunosuppression [11].
Brazil stands out among the developing countries due
to its sustained policy of HIV control, with a history of
25 years of a national control program [6]. Since 1996,
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retroviral drugs [6,12]. Additionally, there is an estab-
lished health service network for qualified management
of HIV infection and opportunistic infections [13]. Since
the beginning of the HAART era, significant impacts
were observed in Brazil, including a significant reduction
of MTCT, AIDS-related hospital admissions, morbidity
and mortality. Since 1996, there was a downward trend
in mortality in this population corresponding to a relative
r e d u c t i o no f6 3 . 6 %i na l lc h i l d r e na n d7 1 . 2 %i nc h i l d r e n
under 5 years of age [6]. However, few children, espe-
cially those from highly vulnerable families still acquire
HIV from their mothers and may develop AIDS. Two
national cohort studies have shown an increased survival
of these children with AIDS [14-17]. The probability of
survival 60 months after diagnosis, which was 53%
among those diagnosed with AIDS between 1983 and
1998, increased to 88% between 1999 and 2002 [14].
Few studies have evaluated changes of clinical patterns
w i t ht h ei n t r o d u c t i o no fH A A R Ti nc h i l d r e n[ 1 8 ] .T h e
aim of this study is to determine the global and specific
frequencies of AIDS-defining illnesses and associated
factors in the two national Brazilian cohorts of children
with AIDS.
Methods
Study Design and Population
This study is based on analysis of two representative mul-
ticenter retrospective cohort studies on survival in Brazi-
lian children with AIDS, infected by mother-to-child
transmission (MTCT). Both studies followed similar meth-
odological procedures, as described in detail previously
[14-17]. Children with HIV/AIDS were defined as those
under 13 years of age, based on the national AIDS case
d e f i n i t i o n si nc h i l d r e n[ 6 ] .I nt h ef i r s tc o h o r t ,A I D Sw a s
defined by the 1994 Brazilian criteria (modified CDC defi-
nition and confirmation by signs) [19]; in the second, by
the 2003 Brazilian criteria (modified CDC definition [clini-
cal immunodeficiency], confirmation by signs, CD4 criter-
ion [laboratorial immunodeficiency-lymphocyte count, by
age strata], death exceptional criterion and death criterion)
[6,20].
The first study included 914 Brazilian children with
AIDS diagnosed between January 1, 1983 and December
31, 1998. The status of children (dead or alive) was
based on the follow-up until death or the end of 2002
[15,17]. The second study was composed of 945 children
with AIDS diagnosed between January 1, 1999 and
December 31, 2002, followed up until death or the end
of 2007 [14,16].
Data analysis
We considered the first clinical event (primary episode)
of each opportunistic illness associated with AIDS in
any time of the children follow-up. Based on the Cen-
ters for Disease Control and Prevention (CDC) defini-
tion [21] and on the Brazilian guidelines [20], we
included 20 severe opportunistic diseases indicative of
AIDS (category “C"-CDC revised classification system
for HIV infection). The opportunistic diseases consid-
ered for analysis are depicted in the Table 1.
Clinical events were diagnosed by pediatricians with
experience in management of HIV-1 infection, and data
were registered in medical records. We reviewed retro-
spectively these medical records regarding the clinical
events. To establish the diagnosis, we followed the Bra-
zilian criteria for definition of AIDS cases in children,
based on presumptive and/or definitive diagnosis [20].
We analyzed separately invasive bacterial infection,
including or not bacterial meningitis or sepsis. The first
group represents largely cases with severe pneumonia.
We verified the occurrence of these opportunistic dis-
eases in the pre-HAART (< 1995) and HAART eras
(1996-2007), using 1996 as a cut point. Odds ratios (OR)
with their respective 95% confidence intervals (95% CI)
were calculated for quantitative comparison of relative fre-
quencies. Additionally, we analyzed variables possibly
associated with the occurrence of AIDS-defining diseases.
Brazilian regions (child’ residence), gender, birth cohort (<
1988, 1989-1995, and 1996-2002), age group (< 1, 1-5, and
6-12 years of age in HIV diagnosis), ART use (in any
time), year of ART initiation (< 1996, and 1996-2002),
vital status (alive or dead), prenatal care, breast-feeding,
and MTCT prophylaxis. Chi-squared and Fisher’s exact
tests were used where applicable. Statistical analysis was
done with the STATA 11.0 software package (Stata Cor-
poration, College Station, USA).
Ethical considerations
Both studies were approved by the Ethical Review Board
of the Center for Reference and Training in STD/AIDS
of São Paulo State, following the guidelines of the
National Health Council.
Results
Epidemiological and demographic characteristics of chil-
dren included in the analysis are detailed in Table 2.
Among these 1,859 children, about half resided in Bra-
zil’s Southeast region. The majority was aged 1-5 years
at diagnosis, with more than two thirds still alive at the
end of follow-up. In total, 1,321 (75.2%) of cases were
diagnosed at an advanced staged as defined by category
“C”. Most cases had their AIDS diagnosis established
between 1996-2002 and at some point used ART for
HIV infection treatment during follow-up, mainly during
1996-2002. A high proportion of mothers had received
prenatal care and breast-fed; MTCT preventive mea-
sures were not used in the majority of cases (Table 2).
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infections during the observation period with a signifi-
cantly lower occurrence of at least one of these events
in the second cohort (OR 0.25, 95% CI 0.20-0.30 p <
0.001). The bivariate analysis of factors associated with
the occurrence of opportunistic infections is depicted in
Table 2. The most important factors associated were:
region of residence within in Brazil (OR 2.68-11.33, as
compared to the Northern region), low age at diagnosis
(OR 2.56), and performance of MTCT prevention mea-
sures (OR 1.58). The use of ART has a protective effect.
Children of the second cohort study and those diag-
nosed after HAART availability also developed signifi-
cantly less opportunistic illnesses. Gender, pre-natal care
and breastfeeding were not significantly associated with
the occurrence of opportunistic diseases (Table 2).
Among the 1,218 children with at least one opportu-
nistic disease, in most cases this disease was defined by
presumptive diagnosis: 651 children (88.2%) in the first
cohort, and 383 (79.8%) in the second (OR 1.90, 1.39-
2.59, p < 0.001). The occurrence of specific opportunis-
tic illnesses is presented in Table 3. In both pre-
HAART and HAART eras, bacterial infections (exclud-
ing meningitis and sepsis) were the most frequent events
(58.6% vs. 34.7%), followed by P. jirovecii pneumonia
(21.9% vs. 13.2%) and bacterial meningitis/sepsis (16.8%
v s .7 . 4 % ) .W eo b s e r v e dad e c r eased proportion of cases
in the second cohort, as compared to the period < 1988.
Considering the pre-HAART and HAART eras, a signif-
icant decrease was also observed (OR 0.29, 0.23-0.37,
p < 0.001) (Table 3).
The analysis related to HIV infection diagnosis in the
pre-HAART and HAART eras shows a statistically signif-
icant reduction for invasive bacterial infection meningitis,
P. jirovecii pneumonia, bacterial meningitis or sepsis,
cryptosporidiosis, and cryptococcosis (Table 2). There
were no reported cases of disseminated coccidioidomyco-
sis and disseminated histoplasmosis in both periods, and
no cases of progressive multifocal leukoencephalopathy
in the HAART era (Table 3).
Discussion
This study represents the first population-based evi-
dence regarding the occurrence and trends of opportu-
nistic illnesses in Brazilian children with AIDS [12,16].
The second national cohort study showed a higher pro-
portion of children exposed to HAART, as compared to
the first study (65% vs. 35%). However, despite the sig-
nificant reduction, opportunistic illnesses still were
important for AIDS-related morbidity, with more than
Table 1 Listing and characteristics of selected AIDS-defining illness in children from the two Brazilian cohorts
AIDS-Defining Illness Characteristics
AIDS Wasting syndrome HIV-related
Bacterial infections (excluding
meningitis or sepsis)
Severe, multiple or recurrent (at least 2 confirmed episodes, 2-year): pneumonia, bone/joint infection, abscess
of internal organs, excluding otitis media, abscesses of skin and mucous membranes and catheter-related
infections
Bacterial meningitis or sepsis Severe, multiple or recurrent (at least 2 confirmed episodes, 2-year)
Candidiasis Esophageal, trachea, bronchi or lungs
Coccidioidomicosis Disseminated
Cryptococcosis Extrapulmonary
Cryptosporidiosis Chronic intestinal, with diarrhea persisting for > 1 month
Cytomegalovirus disease Onset of symptoms after 1 month of age, at a site other than liver, spleen or lymph nodes
Disseminated mycobacterial disease Mycobacterium avium complex or disease caused by Mycobacterium kansasii, at a site other than lungs, skin
or cervical/hilar lymph nodes (except tuberculosis or Hansen’s disease)
Encephalopathy HIV-related
Herpes simplex virus Chronic ulcer(s) in the bronchi, lungs or gastrointestinal tract
Herpes simplex virus, mucocutaneous Persisting for > 1 month affecting children > 1 month of age
Disseminated histoplasmosis At a site other than exclusively pulmonary or cervical/hilar lymph nodes
Isosporiasis Chronic intestinal, persisting for > 1 month
Kaposi’s sarcoma Human herpes virus 8-related
Lymphoma Primary, in brain or lymphoma, non-Hodgkin B-cell lymphoma (unknown immunologic phenotype) and
other lymphomas: large or small, non-cleaved cells (Burkitt or non-Burkitt) or immunoblastic malignant
lymphoma no further specified
Pneumocystis jirovecii pneumonia Interstitial pneumonia
Progressive multifocal
leukoencephalopathy
JC virus-related
Salmonella Sepsis, recurrent (non-typhoid)
Toxoplasmosis of brain Encephalitis with onset after 1 month of age
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recent cohort.
The impact of HAART on the reduction of progres-
sion to AIDS in children has been described repeatedly
[2,3,5,8,10,22-24], even in developing countries [25-27].
However, few population-based studies have evaluated
changes in the pattern of occurrence of diseases asso-
ciated with HIV/AIDS [11,18,28,29]. Our data show a
significant reduction in occurrence of all opportunistic
illness in the HAART era: children that were born, or
diagnosed with HIV/AIDS or had ART initiation after
1996 consistently and significantly reducing the chances
of having opportunistic illness. However we identified a
persisting relative importance of some specific events
such as invasive bacterial diseases. A study conducted in
Italy in a cohort of 1,402 children exposed to HIV
through MTCT and representative of the pre-HAART
(1985-1995) and HAART (1996-2000 and 2001-2005)
p e r i o d ss h o w e dt h ep r o g r e s s i v er e d u c t i o ni nt h er a t eo f
specific clinical events, similar to our study with persist-
ing high rates of serious bacterial infections, particularly
pneumonia [11]. In Brazil, a previous study conducted
in Minas Gerais State (Southeast region) in a referral
center showed that the effectiveness of HAART was
associated with significant reduction in the incidence of
opportunistic infections in 371 children observed
between 1989 and 2003 [18]. However, these data were
not representative for the AIDS population.
In contrast to these previous studies, we observed that
about 1/7 of children still presented P. jirovecii pneumo-
n i ai nt h eH A A R Te r ar e f l e c t i n gt h el a t ed i a g n o s i sa n d
management of HIV infection, despite the significant
reduction in the incidence of this event. In our study
cryptosporidiosis was significantly reduced (more than
Table 2 Epidemiological and demographic characteristics of children, and bivariate analysis of factors associated with
first event of opportunistic illnesses
Total
N (%)
Opportunistic illness
N (%)
OR
(95% CI)
p
Total - 1859 (100.0) 1218 (65.5%) - -
Study cohort 1983-1998 914 (49.2) 738 (80.7) ref
1999-2002 945 (50.8) 480 (50.8) 0.25 (0.20-0.30) < 0.001
Brazilian region (residence) North 107 (5.8) 23 (21.5) ref
Northeast 288 (15.5) 122 (42.4) 2.68 (1.62-4.46) < 0.001
Southeast 931 (50.1) 704 (75.6) 11.33 (7.51-17.09) < 0.001
South 395 (21.2) 267 (67.6) 7.62 (4.78-12.13) < 0.001
Central-West 138 (87.4) 102 (73.9) 10.35 (5.89-18.18) < 0.001
Gender Male 909 (48.9) 594 (65.3) ref
Female 950 (51.1) 624 (65.7) 1.02 (0.84-1.23) 0.88
Birth cohort < 1988 155 (8.3) 127 (81.9) ref
1989-1995 819 (44.1) 582 (71.1) 0.54 (0.35-0.83) 0.006
1996-2002 885 (47.6) 509 (57.5) 0.30 (0.20-0.45) < 0.001
Age Group, HIV diagnosis < 1 year 667 (35.9) 515 (77.2) 2.56 (1.81-3.61) < 0.001
1-5 years 1020 (54.9) 605 (59.3) 1.10 (0.79-1.53) 0.62
6-12 years 172 (9.3) 98 (57.0) ref
Year, HIV diagnosis < 1988 35 (1.9) 28 (80.0) ref
1989-1995 544 (29.3) 449 (82.5) 1.18 (0.50-2.78) 0.65
1996-2002 1280 (68.9) 741 (57.9) 0.34 (0.15-0.76) 0.009
ART use Yes 1555 (83.6) 990 (63.7) 0.58 (0.44-0.77) < 0.001
No 304 (16.4) 228 (75.0) ref
Year, ART initiation < 1996 314 (20.2) 259 (82.5) ref
1996-2002 1241 (79.8) 731 (58.9) 0.30 (0.23-0.41) < 0.001
Children status Alive 1226 (68.9) 695 (56.7) 0.26 (0.20-0.33) < 0.001
Dead 554 (31.1) 463 (83.6) ref
Prenatal care Yes 818 (76.6) 533 (65.2) 1.07 (0.80-1.44) 0.65
No 250 (23.4) 159 (63.6) ref
Breast-feeding Yes 969 (78.7) 628 (64.8) 0.92 (0.69-1.22) 0.56
No 262 (21.3) 175 (66.8) ref
MTCT prophylaxis Yes 254 (15.3) 139 (54.7) ref
No 1404 (84.7) 922 (65.7) 1.58 (1.21-2.07) 0.001
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other diseases (excluding cryptococcosis), despite the
indication of reduction in the proportion of cases in the
second period, there was not a significant difference
between the periods.
Children with AIDS diagnosed between 1996-2002
had a three times lower odds of having opportunistic
infections, as compared to those born before the release
o fa n yA R V .T h u s ,t h e yh a dt h ec h a n c et ob et r e a t e d
with ARV, even in advanced stages of HIV infection
[6,13,14].
Operational issues related to health services examined in
this study, as the realization of prenatal care and adoption
of breastfeeding were not significantly associated with the
occurrence of opportunistic events, the first guidelines for
management of HIV infection and opportunistic diseases
were published in 1994, and the first therapeutic consen-
sus was established in 1996. Expanded further actions for
the prevention of MTCT have occurred since 1999 [6].
Despite these advances in national policy for control of
HIV [13,30], there are indications of operational failures in
these procedures [30-32]. Additionally, regional differences
are important factors that contribute in Brazil to sustain a
non-favorable outcome [16,17,30]. Our study points to a
statistically significant association between non-perfor-
mance of any measure aimed at the prevention of MTCT
(prenatal or childbirth or child) and the occurrence of
these clinical events. Approximately one seventh of the
children had undergone some of the interventions to pre-
vent MTCT, but still acquired HIV and developed AIDS.
Probably, ongoing care and routine monitoring of children
exposed to HIV would have prevented opportunistic ill-
nesses in these cases. The vast majority of children in this
study was born after 1995 (and about half of them after
1997), after wide implementation of MTCT control mea-
sures, evidencing a missed opportunity to prevent HIV
transmission and to start HAART early.
We identified a positive association between the occur-
rences of opportunistic illnesses in all regions of the coun-
try compared with the North region, mainly in the
Southeast where the epidemic is consolidated since the
very beginning [30]. It is noteworthy that the North region
had the lowest proportion of AIDS cases in the two peri-
o d s( 2 %v s .9 % ) .A f t e rt h ep e r i o da n a l y z e di nt h e s et w o
cohorts, the North had a progressive increasing of inci-
dence and mortality rates related to AIDS, which may
have led to changes in the relative occurrence of these
events when comparing regions [13,33].
Children aged < 1 year of age had a higher frequency of
opportunistic illness compared with children aged 1-5
and 6-12 years. This population of children is known to
progress more rapidly to AIDS, with strong evidence of
efficacy of early treatment [4,8,34], which indicates the
need for earlier interventions for the treatment of HIV
Table 3 Occurrence of first event of opportunistic illnesses in the two Brazilian national cohorts of children with AIDS
(n = 1,859)
Cohort-HIV Diagnosis
Opportunistic illness Total
N (%)
Pre-HAART Era
N (%)
HAART Era
N (%)
OR
(95% CI)
P
Invasive bacterial infection (excluding meningitis and septicemia) 791 (42.6) 359 (58.6) 432 (34.7) 2.66 (2.19-3.24) < 0.001
P. jirovecii pneumonia 298 (16.0) 134 (21.9) 164 (13.2) 1.85 (1.44-2.37) < 0.001
Bacterial meningitis or sepsis 195 (10.5) 103 (16.8) 92 (7.4) 2.53 (1.89-3.39) < 0.001
Wasting syndrome 179 (9.6) 91 (10.0) 88 (9.3) 1.09 (0.80-1.48) 0.637
HIV encephalopathy 145 (7.8) 54 (8.8) 91 (7.3) 1.23 (0.86-1.74) 0.270
Cytomegalovirus infection 106 (5.7) 40 (6.5) 66 (5.3) 1.25 (0.83-1.87) 0.289
Candidiasis 101 (5.4) 35 (5.7) 66 (5.3) 1.08 (0.71-1.65) 0.744
Cryptosporidiosis 50 (2.7) 36 (5.9) 14 (1.1) 5.49 (3.13-9.62) < 0.001
Herpes simplex, gingivostomatitis 39 (2.1) 20 (2.2) 19 (2.0) 1.09 (0.58-2.06) 0.872
Cerebral toxoplasmosis 33 (1.8) 13 (2.1) 20 (1.6) 1.33 (0.66-2.68) 0.457
Herpes simplex, mucocutaneous 25 (1.3) 10 (1.6) 15 (1.2) 1.36 (0.61-3.04) 0.521
Disseminated mycobacterial disease 22 (1.2) 9 (1.5) 13 (1.0) 1.41 (0.60-3.31) 0.494
Isosporiasis 21 (1.1) 11 (1.2) 10 (1.1) 1.14 (0.48-2.69) 0.829
Lymphoma 17 (0.9) 7 (1.1) 10 (0.8) 1.43 (0.54-3.75) 0.450
Cryptococcosis 15 (0.8) 10 (1.6) 5 (0.4) 4.12 (1.52-11.14) 0.010
Kaposi’s sarcoma 3 (0.2) 2 (0.3) 1 (0.1) 4.08 (0.44-37.42) 0.254
Leukoencephalopathy 3 (0.2) 3 (0.5) 0 (0.0) - -
Salmonellosis 2 (0.1) 1 (0.2) 1 (0.1) 2.03 (0.13-30.79) 0.551
Histoplasmosis 0 (0.0) 0 (0.0) 0 (0.0) - -
Coccidioidomycosis 0 (0.0) 0 (0.0) 0 (0.0) - -
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adopted measures on their therapeutic guidelines recom-
mending the treatment of all HIV infected children < 1
year of age regardless of clinical symptoms, immunologi-
cal classification or HIV viral load [35].
This study is based on the two unique national
cohorts of children with AIDS for survival analysis with
a representative number of children with AIDS in the
country and its regions. Considering the sheer magni-
tude of the analyzed period (1983-2007), measures
adopted for data collection were standardized, with a
systematic review of all data collected, and minimizing
the effects related to changes in criteria for AIDS cases
definition, management/diagnosis of opportunistic infec-
tions and ART.
The present study has limitations beyond those already
identified and described extensively in our previous publi-
cations on the topic [14-17]. Children in both cohorts had
differing criteria for AIDS case definition, with greater sen-
sitivity in the last one [6]. This may underestimate the
occurrence of opportunistic diseases in this cohort. The
presumptive diagnosis in health services may be related to
difficulties of clinical diagnosis in some cases, the nature
of each specific disease, technical conditions, such as pro-
vision of technical conditions for complementary diagnosis
and experience of medical professionals with HIV/AIDS in
children. Moreover, issues such as underreporting of clini-
cal events and drop-out of some children during the peri-
ods specified in the two survival studies may have biased
our results.
Considering the study period (1983-2007) and the
advance of the Brazilian policy for the control and man-
agement of HIV infection/AIDS even after the introduc-
tion of HAART, the period after 2002 may have
possibly a different pattern of occurrence of opportunis-
tic conditions, indicating the need for further studies.
Conclusions
The present study provides evidence for the reduction of
morbidity related to AIDS-defining opportunistic ill-
nesses in Brazilian children exposed to HIV through
MTCT. This result reflects a period of further consolida-
tion of HAART in a developing country with extensive
commitment of the public sector to providing treatment.
Bacterial diseases remain the most important opportunis-
tic disease. Our study emphasizes the need to continually
expand efforts to prevent MTCT of HIV, early diagnosis
of infection, and improved care of pediatric AIDS
patients.
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